^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ifinatamab deruxtecan (DS-7300)

    i
    Other names: DS-7300, DS7300, DS 7300, DS-7300a, anti-B7-H3/DXd ADC, MABX-9001a/DXd ADC, anti-B7H3 antibody+MAAA-1181a, B7-H3 DXd-ADC, I-Dxd, MK-2400, DS7300a, DS 7300a, IDxd, I Dxd, MK2400, MK 2400
    Company:
    Daiichi Sankyo, Merck (MSD)
    Drug class:
    Topoisomerase I inhibitor, B7-H3-targeted antibody-drug conjugate
    Related drugs:
    Apply
    A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) (NCT04471727)
    Phase 1/2
    Harpoon Therapeutics, Inc., a subsidiary of Mer...
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    12/14/2020
    Primary completion :
    06/30/2027
    Completion :
    06/30/2027
    DLL3
    |
    DLL3 expression
    |
    Tecentriq (atezolizumab) • ifinatamab deruxtecan (DS-7300) • gocatamig (MK-6070)